Loading organizations...
Starbloom Capital is an investment firm funding transformative advancements across deep technology sectors. The firm specializes in supporting breakthrough innovations in longevity biotech, neuroAI, and other burgeoning deep tech industries. It partners with ambitious founders developing scientific and technological solutions poised to expand human capabilities, focusing on discovery's leading edge.
The firm was established in September 2021 by James Fickel. His insight for launching Starbloom Capital stemmed from recognizing the profound, untapped potential in fundamental scientific and technological breakthroughs, particularly those redefining human health and cognitive function. This vision underpins the firm's strategic focus on impactful, long-term investments in frontier science.
Starbloom Capital serves visionary entrepreneurs and scientific teams developing solutions at the intersection of biology, artificial intelligence, and advanced engineering. The firm’s mission is to illuminate and catalyze progress in these frontier areas, working to unlock new paradigms in human potential. It aims to foster a future driven by scientific and technological innovation.
Key people at Starbloom Capital.
Key people at Starbloom Capital.
Starbloom Capital has 6 tracked investments across 5 companies. The latest tracked deal is $105.0M Series C in Cognito Therapeutics in March 2026.